Study S001810

Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET/CT and Cold Stimulation Protocol

ClinicalTrials.gov record

Registration

Registration: NCT07621640
Acronym: BAT-Sema
Study type: INTERVENTIONAL
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 80
Start: 2026-06
Primary completion: 2028-02
Lead sponsor: Hallym University
Conditions: Obesity; Metabolic Syndrome; Brown Adipose Tissue
Interventions: DRUG:Semaglutide (Wegovy®); PROCEDURE:¹⁸FDG-PET/CT with cold stimulation; PROCEDURE:Liver MRI (PDFF + MRE)
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:RS-2026-25483260

Registered primary outcomes

Correlation between baseline BAT metabolic activity (SUVmean and BAT volume on ¹⁸FDG-PET/CT) and percentage body weight loss at 24 weeks of semaglutide treatment [Baseline to 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.